Glibenclamide in cerebral ischemia and stroke

Neurocritical Care

Volumn 20, Issue 2, 2014, Pages 319-333

  Simard, J Marc ^a   Sheth, Kevin N ^b   Kimberly, W Taylor ^c   Stern, Barney J ^a   Del Zoppo, Gregory J ^d   Jacobson, Sven ^e   Gerzanich, Volodymyr ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Remedy Pharmaceuticals Inc   (United States)

Author keywords

Cerebral ischemia; Glibenclamide; RP 1127; Stroke; Stroke Therapy Academic Industry Roundtable (STAIR); Sur1; Sur1 Trpm4 channel

Indexed keywords

ALANINE AMINOTRANSFERASE; ALTEPLASE; ASPARTATE AMINOTRANSFERASE; GLIBENCLAMIDE; RP 1127; SULFONYLUREA RECEPTOR 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN EDEMA; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL DEATH; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVATION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; LOADING DRUG DOSE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; UPREGULATION; ANIMAL; STROKE;

ANIMALS; BRAIN EDEMA; BRAIN ISCHEMIA; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; STROKE;

EID: 84896536524     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-013-9923-1     Document Type: Review

References (84)

1. Truelsen T, Begg S, Mathers C. The global burden of cerebrovascular disease. http://www.who.int/healthinfo/statistics/bod- cerebrovasculardiseasestroke.pdf. Accessed 10 Jan 2013.
2. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: Heart Disease and Stroke Statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:143-52.
3. Hacke W, Schwab S, Horn M, Spranger M, De GM, von KR. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53:309-15. (Pubitemid 26110085)
4. Berrouschot J, Sterker M, Bettin S, Koster J, Schneider D. Mortality of space-occupying ('malignant') middle cerebral artery infarction under conservative intensive care. Intensive Care Med. 1998;24:620-3. (Pubitemid 28344766)
5. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42:1952-5.
6. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924-8. (Pubitemid 351619542)
7. Singer OC, Hamann GF, Misselwitz B, Steinmetz H, Foerch C. Time trends in systemic thrombolysis in a large hospital-based stroke registry. Cerebrovasc Dis. 2012;33:316-21.
8. Jauss M, Schutz HJ, Tanislav C, Misselwitz B, Rosenow F. Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy. Eur J Neurol. 2010;17:555-61.
9. Bryan J, Munoz A, Zhang X, et al. ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007;453:703-18. (Pubitemid 46192541)
10. Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res. 2008;102:164-76. (Pubitemid 351651120)
11. Aittoniemi J, Fotinou C, Craig TJ, de WH, Proks P, Ashcroft FM. Review. SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos Trans R Soc Lond B Biol Sci. 2008;364:257-67.
12. Woo SK, Kwon MS, Ivanov A, Gerzanich V, Simard JM. The sulfonylurea receptor 1 (sur1)-transient receptor potential melastatin 4 (trpm4) channel. J Biol Chem. 2013;288:3655-67.
13. Yamada K, Inagaki N. Neuroprotection by KATP channels. J Mol Cell Cardiol. 2005;38:945-9.
14. Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cereb Blood Flow Metab. 2012;32:1699-717.
15. Simard JM, Woo SK, Gerzanich V. Transient receptor potential melastatin 4 and cell death. Pflugers Arch. 2012;464:573-82.
16. Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006;12:433-40.
17. Simard JM, Tsymbalyuk N, Tsymbalyuk O, Ivanova S, Yurovsky V, Gerzanich V. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke. 2010;41:531-7.
18. Mehta RI, Ivanova S, Tosun C, Castellani RJ, Gerzanich V, Simard JM. Sulfonylurea receptor 1 expression in human cerebral infarcts. J Neuropathol Exp Neurol. 2013;72:871-83.
19. Loh KP, Ng G, Yu CY, et al. TRPM4 inhibition promotes angiogenesis after ischemic stroke. Pflugers Arch. 2013. doi:10.1007/s00424-013-1347-4.
20. Gerzanich V, Woo SK, Vennekens R, et al. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nat Med. 2009;15:185-91.
21. 2+ signals and neuronal death in brain ischemia. Stroke. 2007;38:674-6.
22. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium. 2003;34:325-37. (Pubitemid 37021228)
23. Liss B, Roeper J. Molecular physiology of neuronal K-ATP channels (review). Mol Membr Biol. 2001;18:117-27. (Pubitemid 32666791)
24. Pelletier MR, Pahapill PA, Pennefather PS, Carlen PL. Analysis of single K(ATP) channels in mammalian dentate gyrus granule cells. J Neurophysiol. 2000;84:2291-301.
25. Sullivan HC, Harik SI. ATP-sensitive potassium channels are not expressed in brain microvessels. Brain Res. 1993;612:336-8. (Pubitemid 23167301)
26. Woo SK, Kwon MS, Geng Z, et al. Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of Abcc8. J Cereb Blood Flow Metab. 2012;32:525-36.
27. Simard JM, Woo SK, Tsymbalyuk N, et al. Glibenclamide-10-h treatment window in a clinically relevant model of stroke. Transl Stroke Res. 2012;3:286-95.
28. Simard JM, Tsymbalyuk O, Ivanov A, et al. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest. 2007;117:2105-13. (Pubitemid 47219555)
29. Simard JM, Geng Z, Woo SK, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2009;29:317-30.
30. Kunte H, Busch MA, Trostdorf K, et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol. 2012;72:799-806.
31. Chen M, Dong Y, Simard JM. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci. 2003;23:8568-77. (Pubitemid 37158756)
32. Simard JM, Woo SK, Bhatta S, Gerzanich V. Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr Opin Pharmacol. 2008;8:42-9. (Pubitemid 351168694)
33. + channels in cardiac muscle. J Pharmacol Exp Ther. 1992;262:71-9.
34. Tomiyama Y, Brian JE Jr, Todd MM. Cerebral blood flow during hemodilution and hypoxia in rats : role of ATP-sensitive potassium channels. Stroke. 1999;30:1942-7.
35. Nedergaard M, Kraig RP, Tanabe J, Pulsinelli WA. Dynamics of interstitial and intracellular pH in evolving brain infarct. Am J Physiol. 1991;260:R581-8.
36. Ortega FJ, Gimeno-Bayon J, Espinosa-Parrilla JF, et al. ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats. Exp Neurol. 2012;235:282-96.
37. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007;6:258-68. (Pubitemid 46228081)
38. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788:842-57.
39. Simard JM, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke. 2009;40:604-9.
40. Ortega FJ, Jolkkonen J, Mahy N, Rodriguez MJ. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2012;33:356-64.
41. Wali B, Ishrat T, Atif F, Hua F, Stein DG, Sayeed I. Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. Stroke Res Treat. 2012;2012:460909. doi:10.1155/2012/460909.
42. Petullo D, Masonic K, Lincoln C, Wibberley L, Teliska M, Yao DL. Model development and behavioral assessment of focal cerebral ischemia in rats. Life Sci. 1999;64:1099-108. (Pubitemid 29152027)
43. Virtanen T, Sivenius J, Jolkkonen J. Dehydration and stress do not explain severe weight loss after experimental stroke in rats. J Animal Vet Adv. 2003;2:247-52.
44. Virtanen T, Jolkkonen J, Sivenius J. Re: External carotid artery territory ischemia impairs outcome in the endovascular filament model of middle cerebral artery occlusion in rats. Stroke. 2004;35:e9-10.
45. Simard JM, Geng Z, Silver FL, et al. Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci. 2012;1268:95-107.
46. Abdallah DM, Nassar NN, Abd-El-Salam RM. Glibenclamide ameliorates ischemia-reperfusion injury via modulating oxidative stress and inflammatory mediators in the rat hippocampus. Brain Res. 2011;1385:257-62.
47. Figura M, Chilton L, Liacini A, et al. Blockade of K(ATP) channels reduces endothelial hyperpolarization and leukocyte recruitment upon reperfusion after hypoxia. Am J Transplant. 2009;9:687-96.
48. Da Silva-Santos JE, Santos-Silva MC, Cunha FQ, Assreuy J. The role of ATP-sensitive potassium channels in neutrophil migration and plasma exudation. J Pharmacol Exp Ther. 2002;300:946-51. (Pubitemid 34165000)
49. Pompermayer K, Amaral FA, Fagundes CT, et al. Effects of the treatment with glibenclamide, an ATP-sensitive potassium channel blocker, on intestinal ischemia and reperfusion injury. Eur J Pharmacol. 2007;556:215-22. (Pubitemid 46074006)
50. Pompermayer K, Souza DG, Lara GG, et al. The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats. Kidney Int. 2005;67:1785-96. (Pubitemid 40577713)
51. Nistico R, Piccirilli S, Sebastianelli L, Nistico G, Bernardi G, Mercuri NB. The blockade of K(+)-ATP channels has neuroprotective effects in an in vitro model of brain ischemia. Int Rev Neurobiol. 2007;82:383-95.
52. Huang H, Gao TM, Gong L, Zhuang Z, Li X. Potassium channel blocker TEA prevents CA1 hippocampal injury following transient forebrain ischemia in adult rats. Neurosci Lett. 2001;305:83-6. (Pubitemid 33762771)
53. Ortega FJ, Jolkkonen J, Rodriguez MJ. Microglia is an active player in how glibenclamide improves stroke outcome. J Cereb Blood Flow Metab. 2013;33:1138-9.
54. Schaller B, editor. Cerebral ischemic tolerance: from animal models to clinical relevance. New York: Nova Science Publishers; 2004.
55. Durukan A, Tatlisumak T. Preconditioning-induced ischemic tolerance: a window into endogenous gearing for cerebroprotection. Exp Transl Stroke Med. 2010;2:2.
56. Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab. 2002;22:1283-96. (Pubitemid 35285085)
57. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26:248-54. (Pubitemid 36556155)
58. + channels in cerebral ischemic preconditioning. Proc Natl Acad Sci U S A. 1995;92:4666-70.
59. Sorimachi T, Nowak TS Jr. Pharmacological manipulations of ATP-dependent potassium channels and adenosine A1 receptors do not impact hippocampal ischemic preconditioning in vivo: evidence in a highly quantitative gerbil model. J Cereb Blood Flow Metab. 2004;24:556-63. (Pubitemid 38608288)
60. Munoz A, Nakazaki M, Goodman JC, et al. Ischemic preconditioning in the hippocampus of a knockout mouse lacking SUR1-based K(ATP) channels. Stroke. 2003;34:164-70. (Pubitemid 36070818)
61. Hamann GF. Clinical aspects of ischemic tolerance in the brain. In: Schaller B, editor. Cerebral ischemic tolerance: from animal models to clinical relevance. New York: Nova Science Publishers; 2004. p. 115-9.
62. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007;38:2526-30. (Pubitemid 47329632)
63. No authors listed. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-2758.
64. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-50.
65. Tosun C, Koltz MT, Kurland DB, et al. The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity. Brain Sci. 2013;3:215-38.
66. Toyota S, Graf R, Valentino M, Yoshimine T, Heiss WD. Prediction of malignant infarction: perifocal neurochemical monitoring following prolonged MCA occlusion in cats. Acta Neurochir Suppl. 2003;86:153-7.
67. Toyota S, Graf R, Valentino M, Yoshimine T, Heiss WD. Malignant infarction in cats after prolonged middle cerebral artery occlusion: glutamate elevation related to decrease of cerebral perfusion pressure. Stroke. 2002;33:1383-91. (Pubitemid 34517064)
68. del Zoppo GJ, Copeland BR, Harker LA, et al. Experimental acute thrombotic stroke in baboons. Stroke. 1986;17:1254-65. (Pubitemid 17008967)
69. Fukuda S, del Zoppo GJ. Models of focal cerebral ischemia in the nonhuman primate. ILAR J. 2003;44:96-104. (Pubitemid 36410963)
70. West GA, Golshani KJ, Doyle KP, et al. A new model of cortical stroke in the rhesus macaque. J Cereb Blood Flow Metab. 2009;29:1175-86.
71. Bahjat FR, Williams-Karnesky RL, Kohama SG, et al. Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. J Cereb Blood Flow Metab. 2011;31:1229-42.
72. Cook DJ, Tymianski M. Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics. 2012;9:371-9.
73. Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med. 2012;4:154ra133.
74. Zabramski JM, Spetzler RF, Selman WR, et al. Naloxone therapy during focal cerebral ischemia evaluation in a primate model. Stroke. 1984;15:621-7. (Pubitemid 14090234)
75. Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhaupl K. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke. 2001;32:2029-32. (Pubitemid 32868092)
76. Favilla CG, Mullen MT, Ali M, Higgins P, Kasner SE. Sulfonylurea use before stroke does not influence outcome. Stroke. 2011;42:710-5.
77. Silver FL, Fang J, Robertson AC, Casaubon L, Kapral MK. Possible neuroprotective effects of sulfonylureas in diabetic patients with acute ischemic stroke. Stroke. 2009;40:51.
78. Mishra MK, Ray D, Barik BB. Microcapsules and transdermal patch: a comparative approach for improved delivery of antidiabetic drug. AAPS PharmSciTech. 2009;10:928-34.
79. Zhou Y, Fathali N, Lekic T, Tang J, Zhang JH. Glibenclamide improves neurological function in neonatal hypoxia-ischemia in rats. Brain Res. 2009;1270:131-9.
80. Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK glucose insulin in stroke trial (GIST-UK). Lancet Neurol. 2007;6:397-406. (Pubitemid 46551852)
81. Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke. 2008;39:384-9. (Pubitemid 351619460)
82. Johnston KC, Hall CE, Kissela BM, Bleck TP, Conaway MR. Glucose regulation in acute stroke patients (GRASP) trial: a randomized pilot trial. Stroke. 2009;40:3804-9.
83. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-77. (Pubitemid 43358067)
84. Arboix A. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke. Stroke. 2007;38:2413-4. (Pubitemid 47329615)